中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

185 records (took 0.015 seconds)

    DETERMINATION OF TRACERS WITHIN SUBJECTS
    13.
    发明申请
    DETERMINATION OF TRACERS WITHIN SUBJECTS 审中-公开
    确定受试者间的踪迹

    公开(公告)号：WO2010110916A2

    公开(公告)日：2010-09-30

    申请号：PCT/US2010/000919

    申请日：2010-03-26

    Applicant: SEVENTH SENSE BIOSYSTEMS, INC. ,  LEVINSON, Douglas, A.

    Inventor： LEVINSON, Douglas, A.

    IPC: A61K47/48

    CPC classification number: A61K49/006 ,  A61K47/549 ,  A61K47/60 ,  A61K47/62 ,  A61K49/0006

    Abstract: The present invention generally relates to the use of tracers, for example, to track a substance that has been administered to a subject. A tracer may be separate from the substance to be administered, or in some cases, the tracer and the substance are chemically bonded to each other. When administered to a subject (e.g., ingested), the tracer and the substance to be administered may be absorbed and/or metabolized by the subject, and the pharmacokinetic activity of the tracer within the subject may be related to the pharmacokinetic activity of the substance. Thus, by following the pharmacokinetic activity of the tracer, the pharmacokinetic activity of the substance may be determined. The tracer itself may be determined within a subject using any suitable method, depending on the tracer. As an example, the tracer may be determined by administering an indicator able to interact with the tracer. For instance, the indicator may be applied to the skin of the subject, and the indicator may give a different visual appearance based on the concentration of the tracer, or otherwise exhibit a determinable change in a property of the indicator. Other aspects of the invention are generally directed to methods of making or using tracers, methods of promoting the making or use of such tracers, kits involving such tracers, and the like.

    Abstract translation: 本发明一般涉及示踪剂的使用，例如，追踪已经施用于对象的物质。 示踪剂可以与要施用的物质分开，或者在某些情况下，示踪剂和物质彼此化学键合。 当施用于受试者（例如摄入的）时，示踪剂和待施用的物质可以被受试者吸收和/或代谢，受试者内示踪剂的药代动力学活性可以与该物质的药代动力学活性相关 。 因此，通过跟踪示踪剂的药代动力学活性，可以确定该物质的药代动力学活性。 示踪剂本身可以使用任何合适的方法在受试者内确定，取决于示踪剂。 作为例子，示踪剂可以通过施用能够与示踪剂相互作用的指示剂来确定。 例如，指示剂可以施加到受试者的皮肤上，并且指示剂可以基于示踪剂的浓度给出不同的视觉外观，或者以其他方式呈现指示剂性质的可确定的变化。 本发明的其它方面通常涉及制造或使用示踪剂的方法，促进制造或使用这种示踪剂的方法，涉及这种示踪剂的试剂盒等。

    CONTRAST AGENT FORMULATIONS FOR THE VISUALIZATION OF THE LYMPHATIC SYSTEM
    17.
    发明申请
    CONTRAST AGENT FORMULATIONS FOR THE VISUALIZATION OF THE LYMPHATIC SYSTEM 审中-公开
    对比剂制剂用于可视化淋巴系统

    公开(公告)号：WO2006037803A1

    公开(公告)日：2006-04-13

    申请号：PCT/EP2005/055071

    申请日：2005-10-06

    Applicant: BRACCO IMAGING SpA ,  DE HAEN, Christoph

    Inventor： DE HAEN, Christoph

    IPC: A61K49/22 ,  A61K49/00

    CPC classification number: A61K49/223 ,  A61K31/22 ,  A61K49/006

    Abstract: The present invention relates to the field of diagnostic imaging and provides compositions of ultrasound contrast agents, particularly gas-filled microvesicles suspensions, in combination with vital dyes. The compositions of the invention are advantageously used in the visualization of the lymphatic system, particularly for the detection of the sentinel lymph node or nodes of a tumor.

    Abstract translation: 本发明涉及诊断成像领域，并提供与活性染料组合的超声造影剂，特别是气体填充的微泡悬浮液的组合物。 本发明的组合物有利地用于淋巴系统的可视化，特别是用于检测肿瘤的前哨淋巴结或淋巴结。

    METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC)
    18.
    发明申请
    METHODS OF CHEMICAL SYNTHESIS AND PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) 审中-公开
    化学合成和纯化包括氯化亚甲基氯化铵（MTC）的二氨基苯甲酸盐化合物的方法

    公开(公告)号：WO2006032879A2

    公开(公告)日：2006-03-30

    申请号：PCT/GB2005/003634

    申请日：2005-09-21

    Applicant: TAURX THERAPEUTICS PTE. LTD. ,  STOREY, John, Mervyn, David ,  SINCLAIR, James, Peter ,  MARSHALL, Colin ,  TAN, Han, Wan ,  WISCHIK, Claude, Michel

    Inventor： STOREY, John, Mervyn, David ,  SINCLAIR, James, Peter ,  MARSHALL, Colin ,  TAN, Han, Wan ,  WISCHIK, Claude, Michel

    IPC: C07D279/18

    CPC classification number: A61K31/5415 ,  A61K9/0019 ,  A61K49/006 ,  C07D279/18 ,  C09B19/02 ,  G01N33/52 ,  Y02A50/393

    Abstract: This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as "diaminophenothiazinium compounds") including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases.

    Abstract translation: 本发明一般涉及化学合成和纯化领域，更具体地涉及合成和纯化某些3,7-二氨基 - 吩噻嗪-5-肟化合物（本文中称为“二氨基吩噻嗪鎓化合物”）的方法，包括氯化亚铁（MTC） （也称为亚甲蓝）。 在一个实施方案中，该方法包括以下步骤：按顺序：亚硝基化（NOS）; 亚硝酰还原（NR）; 硫代磺酸形成（TSAF）; 氧化偶合（OC）; Cr（VI）还原（CR）; 两性离子中间体（IAPOZI）的分离和纯化; 闭环（RC）; 氯化物盐形成（CSF）; 一种：硫化物处理（ST）; 二甲基二硫代氨基甲酸酯处理（DT）; 碳酸盐处理（CT）; 乙二胺四乙酸处理（EDTAT）; 有机萃取（OE）; 和重结晶（RX）。 本发明还涉及所得的（高纯度）化合物，包含它们的组合物（例如片剂，胶囊）及其在灭活病原体的方法中的用途，以及治疗和诊断方法等，例如对于tau蛋白病 ，阿尔茨海默病（AD），皮肤癌，黑素瘤，病毒性疾病，细菌性疾病或原生动物疾病。

    ヒアルロン酸のセンチネルリンパ節同定への応用
    19.
    发明申请
    ヒアルロン酸のセンチネルリンパ節同定への応用 审中-公开
    羟丙酸对小鼠淋巴细胞标志物的鉴定应用

    公开(公告)号：WO2005117995A1

    公开(公告)日：2005-12-15

    申请号：PCT/JP2005/010635

    申请日：2005-06-03

    Applicant: 北山 丈二

    Inventor： 北山 丈二

    IPC: A61K49/00

    CPC classification number: A61K47/36 ,  A61K9/0019 ,  A61K49/006

    Abstract: 本発明は、　正確かつ簡便で安全なセンチネルリンパ節の検出剤および検出方法を提供する。本発明によれば、着色成分とヒアルロン酸成分との混合成分により、正確かつ簡便で安全にセンチネルリンパ節を検出することができる。

    Abstract translation: 本发明提供了用于前哨淋巴结的准确，简单和安全的检测剂以及用于检测节点的方法。 根据本发明，可以准确，简单且安全地使用着色组分和透明质酸的混合物来检测前哨淋巴结。

    POLARIZED LIGHT DEVICES AND METHODS
    20.
    发明申请
    POLARIZED LIGHT DEVICES AND METHODS 审中-公开
    极化光器件和方法

    公开(公告)号：WO2004083944A2

    公开(公告)日：2004-09-30

    申请号：PCT/US2004/008251

    申请日：2004-03-18

    Applicant: THE GENERAL HOSPITAL CORPORATION ,  YAROSLAVSKY, Anna, M. ,  ANDERSON, Rox, R.

    Inventor： YAROSLAVSKY, Anna, M. ,  ANDERSON, Rox, R.

    IPC: G02F

    CPC classification number: A61B5/444 ,  A61B5/0059 ,  A61B5/0088 ,  A61B5/14556 ,  A61K49/006 ,  G01N21/21

    Abstract: The present invention is directed to a novel multi-spectral contrast agent-enhanced polarized light technique that enables rapid imaging of large tissue fields. The imaging device includes a tunable monochromatic light source and a CCD camera. Linear polarizers are placed into both the incident and collected light pathways in order to limit the measurement volume to the superficial tissue layers. To enhance the tumor contrast in the image, aqueous solutions of toluidine blue or methylene blue are topically applied.

    Abstract translation: 本发明涉及能够快速成像大组织场的新型多光谱造影剂增强偏振光技术。 成像装置包括可调单色光源和CCD照相机。 线性偏振器被放置在入射和收集的光通路中，以便将测量体积限制到表面组织层。 为了增强图像中的肿瘤对比度，局部应用甲苯胺蓝或亚甲基蓝的水溶液。

Patent Agency Ranking